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Making a Mountain Out of a Molehill:
NRAS, Mosaicism, and Large
Congenital Nevi
Pedram Gerami1 and Amy S. Paller1
Linking phenotypic patterns of melanocytic neoplasia to specific gene mutations
allows more precise predicting of clinical behavior and response to targeted
therapy. In this issue, Kinsler et al. provide evidence that multiple congenital nevi
with central nervous system lesions are likely exclusively the result of mosaic
mutations in NRAS. We discuss the link between mosaic NRAS mutations, cellular
senescence, and clinical phenotype in these nevi.
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Activation of specific signaling path-
ways through postzygotic gene mutation
(mosaicism) has been shown to be
responsible for the development of both
benign and malignant tumors of skin.
Commonly, these mutations constitu-
tively activate an isoform of the RAS
family of GTPase proteins, HRAS,
NRAS, or KRAS, and involve hot spot
mutations at codons 12, 13, and 61.
These RAS proteins have GTP/GDP
binding and GTPase activity, allowing
them to function as binary switches for
pathway activation, leading to increased
cell proliferation.
Neurologic alterations in association with
large congenital melanocytic nevi and
satellite lesions are the result of a
common NRAS mutation
Congenital melanocytic nevi (CMNs)
are benign clonal proliferations of cells
of neural crest origin that occur overall
in B1% of infants. CMNs have been
classified based on size as small
(o1.5 cm in diameter in the adult),
medium sized (1.5–20 cm), large
(420 cm), and sometimes giant
(440 cm) (Alikhan et al., 2012). In con-
trast to the common occurrence of small
CMNs, larger CMNs have an estimated
incidence of 1 in 20,000 individuals.
Neuromelanosis of the meninges and
brain parenchyma (neurocutaneous
melanosis (NCM)) may be associated
with CMNs, particularly in large CMNs
with X3 (multiple) satellite nevi;
whether there is a greater risk of neuro-
melanosis with truncal large CMNs has
been controversial. Symptomatic NCM
has a poor prognosis because of
functional impairment and a high rate
of transformation of central nervous
system melanocytic lesions to mela-
noma, with more than half of affected
patients dying within 3 years of
diagnosis. NCM can be detected by
T1-weighted magnetic resonance
imaging (MRI) images, but the absence
of neuromelanosis by MRI does not rule
out its presence and finding neuromel-
anosis does not predict its course. NCM-
associated signs tend to manifest by 2 to
3 years of age, but a subset of patients
present later in childhood. These signs
can include hydrocephalus, seizures,
evidence of increased intracranial pre-
ssure (headache, vomiting, lethargy),
developmental delay, hypotonia, neuro-
genic bowel and bladder dysfunction,
sensorimotor defects, and cranial nerve
palsies. The percentage of patients with
large CMNs who develop neurome-
lanosis (2.5–45%) and with NCM who
become symptomatic (4–68%) varies
greatly, probably reflecting the small
size of most studies and specialty of
the authors. In a survey of 599
individuals with large or giant truncal
CMNs through the Nevus Network, a
patient support group, 7.5% had NCM
based on MRI and/or symptoms, and
4.8% had symptomatic NCM. Multiple
satellite nevi were noted in at least 87%
of individuals with NCM, and 34% with
symptomatic NCMs died (Bett, 2006).
In common acquired pigmented nevi,
small CMNs, and in 50–60% of mela-
nomas, hot spot V600E mutations in
BRAF, encoding a signaling molecule
downstream of RAS, predominate. The
HRAS isoform of the RAS gene is
mutated in B12% of Spitz nevi, but is
infrequently mutated in conventional
nevi or melanomas. On the other hand,
the majority of giant, large, and med-
ium-sized CMNs, as well as 20% of
acquired pigmented nevi and 15–20%
of melanomas, result from NRAS acti-
vating mutations. Mutations in BRAF
and NRAS are almost invariably
mutually exclusive, suggesting that they
may function on the same RAS/extra-
cellular signal–regulated kinase (ERK)
signaling pathway (Figure 1).
One question that has not been
addressed previously is whether CMNs
at multiple body sites, often as satellites
to a giant CMN, are clonal or arise de
novo as different mutations in neuroec-
todermal cells. In addition, the under-
lying mutations in neuromelanosis and
their relation to coexistent CMNs have
not been explored. In this issue, Kinsler
et al. (2013) evaluated lesional samples
of congenital nevi and associated
abnormal nervous system tissue and/or
melanomas from 15 patients with at
least 3 congenital nevi. All but one
had a medium-size to giant CMN, and
most had at least 50 satellite lesions. Of
the 15 patients, 12 showed an NRAS
mutation at codon 61 (Q61K more often
than Q61R) within the tissue samples
from the large CMN and in at least one
additional congenital nevus, if available.
All 11 melanocytic and nonmelanocytic
neurologic lesions from 5 of these
patients also had matching NRAS
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codon 61 mutations. None of the blood
samples or clinically unaffected tissue
samples carried this mutation, providing
evidence that postzygotic mutations in
NRAS involving the skin and central
nervous system underlie the develop-
ment of multiple CMNs or large CMNs
in association with neuroectodermal
abnormalities, particularly leptomenin-
geal melanosis.
Multisite clonal mutations and patterning
in mosaic gene disorders of melanocytes
The underlying mechanism for the
neurocutaneous patterning of mosaicism
in melanocyte genes has been poorly
understood. Keratinocyte gene mosai-
cism, as occurs in epidermal nevi and
nevus sebaceus, is expressed pheno-
typically along lines of Blaschko, the
lines of embryologic development
of skin. In contrast, small- to medium-
sized congenital (and acquired)
pigmented nevi are round to oval and
large and giant CMNs tend to be gar-
ment-like, resembling a bathing suit,
shirt, or cuff (Torrelo et al., 2005).
These pattern differences likely reflect
the different migratory patterns of
cells during embryogenesis (i.e.,
keratinocyte vs. melanocyte), and they
may depend on the timing of muta-
tion occurrence during embryogenesis
and the effect of the underlying
gene mutation on cell proliferation,
migration, and survival.
Kinsler et al. (2013) provide evidence
that multiple nevus sites and associated
neurologic lesions show the same
mutation, confirming the clonality of
these lesions. Theoretically, a mutation
that occurs early in neuroectodermal
embryogenesis would lead to lesions
with the same mutation at more than
one site (i.e., leptomeningeal and skin
lesions), as well as to larger and
greater numbers of cutaneous nevi that
harbor the same mutation. The
phenotypic characteristics of nevi with
NRAS Q61 mutations (larger CMNs,
often multiple) versus BRAF V600
mutations (smaller CMNs) likely also
reflect the function of NRAS versus
BRAF gene products. Activated NRAS
leads to signaling through both ERK and
the phosphatidylinositol 3-kinase
(PI3K)/AKT pathway, in contrast to
activation of only ERK signaling with
activated BRAF. In addition to
increasing cell proliferation, PI3K/AKT
activation promotes melanocyte
survival and directional migration
through Rac1 stimulation (Li et al.,
2012); the ability of NRAS mutations
to stimulate both pathways concurrently
may contribute to the relatively poor
prognosis of leptomeningeal melanosis
and the greater thickness and
mitotic rate of melanomas with NRAS
Q61 versus BRAF V600 mutations as
well. An individual’s genome may also
influence the occurrence and biological
characteristics of CMNs. Kinsler et al.
(2012) have previously identified an
increased frequency of CMNs, both
small and large, in individuals with
certain alleles of MC1R, encoding the
melanocortin-1 receptor; these alleles
are also associated with having red
hair, fair skin, photosensitivity, and a
propensity to develop acquired nevi and
melanoma.
Although mutations in NRAS, BRAF,
and HRAS are known to activate the
mitogen-activated protein kinase path-
way and lead to melanocytic cell pro-
liferation, these mutations also result in
oncogene-induced senescence (OIS),
which eventually ceases melanocytic
proliferation unless overcome by other
genetic aberrations. A number of
mechanisms for OIS have been
described, particularly (1) replicative
senescence related to progressive
Clinical Implications
Multiple congenital melanocytic nevi with associated neurologic lesions
are the result of the same mosaic mutations in NRAS.
 The greater size, higher number, and distant sites of involvement of the
large congenital nevi that result from NRAS mutations may relate to
delayed oncogene-induced senescence.
 Targeting activating mutations in NRAS, inhibiting NRAS membrane
localization for activation, and targeting downstream signaling pathways
are potential approaches to restore senescence and treat symptomatic
neurocutaneous melanosis and melanomas arising in a background of
large or multiple congenital melanocytic nevi.
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Figure 1. NRAS, when activated, signals through both mitogen-activated protein (MAP) kinase
(extracellular signal–regulated kinase (ERK)) and AKT pathways. GDP, guanosine diphosphate; GTP,
guanosine triphosphate; MEK, MAPK/ERK kinase; PI3K, phosphatidylinositol 3-kinase.
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shortening of telomeres; (2) oncogenic
activation of P53 or P16 pathways; and
(3) activation of DNA damage response
pathways. The exclusive presence of
NRAS mutations in giant and multiple
CMNs, in contrast to the BRAF muta-
tions seen in most small to medium-
sized isolated CMNs or the HRAS
mutations seen in B12% of Spitz nevi,
suggest that activating mutations in
NRAS induce a more prolonged phase
than other Ras activating mutations of
melanocytic proliferation before OIS,
leading to more extensive skin involve-
ment (Ichii-Nakato et al., 2006).
Elucidating the mechanism of OIS in
large and multiple CMNs with NRAS
mutations may provide insight into
mechanisms of escape from senesce-
nce in all NRAS-mutated melanocytic
neoplasms.
Gene mutation and chromosomal copy
number changes correlate with
progression to melanoma
In contrast to the relatively low risk of
nevus transformation to melanoma with
small CMNs, giant CMNs are recog-
nized to have a lifetime risk of malig-
nant transformation of B5%, with
greater risk a function of nevus size
and number of satellites (Alikhan et al.,
2012). Most malignancies in giant
CMNs occur during childhood. Indeed,
of the patients described by Kinsler et al.
(2013) transformation to melanoma
occurred in a CMN in 1 of the 15 repor-
ted cases (6.7%) and in the leptomenin-
geal melanosis in 2 of 15. Presumably,
increases in the number and duration of
proliferative melanocytic cells result in a
larger field of partially transformed cells
that are primed for secondary events
such as second gene mutations or
chromosomal copy number changes
needed for transformation.
Giant CMNs also have a predilection
toward the development of benign
proliferative nodules. These expansile
nodular proliferations of melanocytes
often show worrisome histologic fea-
tures, including cellular atypia and pro-
minent mitotic activity. Histologic
distinction from melanoma is often dif-
ficult. Studies with comparative geno-
mic hybridization (CGH) have shown
whole chromosomal changes, particu-
larly loss of chromosomes 7, 9, or 10
(Bastian et al., 2002). These changes
likely result in a temporary escape
from OIS, but ultimately activate other
mechanisms of cellular senescence and
remain benign. In contrast, melano-
mas arising in CMNs typically harbor
gains and losses of chromosomal
fragments, in addition to whole
chromosomal changes. A host of
chromosomal copy number aberrations
were seen by array CGH in both
melanoma cases in the report of
Kinsler et al. (2013), including many
gains and losses of chromosomal
fragments, solidifying the diagnosis of
melanoma. Interestingly, several recent
studies have noted elevated expression
of C-MYC, encoded on chromosome
8q24, as one key mechanism of
overcoming RAS OIS (Hydbring et al.,
2010). This is supported by the gain
in chromosome 8 in one of the NRAS-
mutated melanomas described by
Kinsler et al. (2013) and some
of our own recent studies (Figure 2;
P Gerami et al., unpublished data).
Hence, cytogenetic analysis may help
in more precisely identifying the
development of melanoma and the
precise extent of melanoma disease
in patients with complex clinical phe-
notypes, including leptomeningeal
melanocytosis.
Future therapies targeting NRAS for large
CMNs, associated neurologic
abnormalities, and melanomas
The case series by Kinsler et al. (2013)
demonstrates that the combination of
gene mutational analysis, cytogenetic
analysis, and clinical phenotype may
guide therapeutic strategies in the era
of molecular diagnostics and targeted
therapy. In contrast to the availability of
vemurafenib for treating BRAF V600Eþ
metastatic melanoma, however, no
currently available therapy specifically
combats NRAS mutations. Nevertheless,
targeting NRAS is a priority for
melanoma research and for NCM,
given the new recognition that virtually
all harbor a Q61K or Q61R mutation. A
systemically administered agent that
traverses the blood–brain barrier would
be required for management of neuro-
logic involvement, but even a topically
applied agent could be used for larger
CMNs. Current strategies under consid-
eration include: (1) inactivation of NRAS
protein through pharmacological inhibi-
tion of membrane localization, which is
required for RAS activity; (2) depletion
of mutant NRAS protein specifically by
small interfering RNA or antisense oli-
gomers; and (3) targeting downstream
signaling of the ERK and PI3K/AKT path-
ways (Kelleher and McArthur, 2012).
Figure 2. Melanoma with 8q24 gains arising in a congenital melanocytic nevus of a 7-year-old child.
(a) Amelanotic nodular melanoma (hematoxylin and eosin; bar¼100mm). Upper inset shows area of
(b) with the melanoma; the lower inset shows area of (c) with the congenital nevus. (b) Sheets of melanoma
cells with epidermal ulceration (bar¼ 100mm). (c) Precursor congenital nevus with nevomelanocytes
tracing adnexa can still be seen (bar¼ 40mm). (d) Fluorescence in situ hybridization (FISH) in the aqua
channel showing melanoma cells with elevated copy numbers of 8q24, which includes the c-myc locus
(bar¼ 20mm).
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Elucidation of the mechanism by which
OIS is overcome in melanomas arising
in these neoplasms will also be an
important step toward improved
therapeutic targeting.
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Nuclear Topology, Epigenetics, and
Keratinocyte Differentiation
Michael W. Hughes1, Wange Lu2 and Cheng-Ming Chuong1,3
Recent progress in epigenetics reveals dynamic chromatin interactions in the
nucleus during development, regeneration, reprogramming, and in disease.
Higher-order chromatin organization is manifested as changes in the topological
distribution of eu-/heterochromatin and in nuclear morphology. We are now able
to gain new knowledge about these changes at the genomic level.
Journal of Investigative Dermatology (2013) 133, 2130–2133. doi:10.1038/jid.2013.261
In pathology, nuclear morphology is
one of the features used to recognize
differentiated cell types as is seen in the
multilobed nuclei of neutrophils, cart-
wheel-shaped nuclei in plasma cells,
and large round nuclei in lymphocytes.
Mature skin fibroblasts, ordinarily hav-
ing elongated and condensed nuclei,
begin to exhibit enlarged and ‘‘pale’’
nuclei in response to injury. Such
features reveal changes in gene expres-
sion profiles in those nuclei. With
See related article on pg 2191
progress in systems biology, we are
now on the verge of understanding the
molecular mechanisms that underly
these changes.
Every somatic cell has identical
genetic content. How can different
genes be expressed in different cell
types or in the same cell type when in
different functional states? Normal cell
behavior requires a series of coordinated
interactions between cells and their
local environments to induce specific
gene expression patterns. Global gene
expression profiles are achieved by
different epigenetic modulations of
chromatin conformation. Therefore, it
is important to understand how these
processes function during cellular
homeostasis in order to create unique
and specific therapies for disease.
Previously, our understanding of the
role of DNA conformation reflected
gene-specific phenotypes or mutations,
with epigenetic processes left as an
incomprehensible black box. Advances
in genomics and systems biology has
started to reveal the workings of this
black box, leading to a new understanding
of disease in terms of epigenetic
processes and high-order chromatin
organization (Misteli, 2010; Lee and
Young, 2013).
In this issue, Gdula et al. (2013)
characterize the changes in nuclear
shape that take place during epidermal
keratinocyte differentiation. Briefly, the
authors show that basal keratinocytes
possess a vertically orientated,
columnar-shaped nucleus that
gradually becomes a horizontally
shaped spheroid in the uppermost
supra-basal layers. Here we use this
paper as a lead-in (or beacon) to
introduce exemplary papers that
report the epigenetic processes
during keratinocyte differentiation. A
special issue in Cell (14 March 2013)
covers the topic of nuclear dynamics
and includes several up-to-date
reviews for those who wish to
explore this important area further.
Epigenetic processes during development,
reprogramming, and disease
DNA is the blueprint for coordinated
gene expression, resulting in a multitude
of biological processes. The ability to
attain spatiotemporal gene expression
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